S-1: NeOnc Technologies Faces Liquidity Concerns Amidst Clinical Progress

NeOnc Technologies Holdings, Inc. reports significant net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidates NEO100 and NEO212 in clinical trials and acquiring new AI and 3D bioprinting platforms.

Summary

• NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, including primary and secondary brain cancers.
• The company's lead product candidates are NEO100, a purified form of perillyl alcohol (POH) administered intranasally, and NEO212, a conjugated molecule combining temozolomide with perillyl alcohol.
• NEO100 has completed a Phase I clinical trial and is currently in Phase IIa trials for recurrent malignant glioma (Grade IV, IDH1 mutant and Grade III Astrocytoma, IDH1 mutant) and malignant skull-based meningioma.
• NEO212 has completed preclinical testing, received IND approval from the FDA, and began a Phase I/II trial for oral administration in patients with primary and secondary brain tumors in Q4 2023.
• The company reported a net loss of $46,622,106 for the nine months ended September 30, 2025, compared to $9,645,482 for the same period in 2024.
• The accumulated deficit reached $97,230,551 at September 30, 2025, up from $50,608,445 at December 31, 2024.
• Revenue for the nine months ended September 30, 2025, was $39,990, primarily from a humanitarian program, with no significant product sales.
• Operating expenses significantly increased, with share-based compensation at $25,964,096 and advisory fees at $11,737,806 for the nine months ended September 30, 2025.
• The company has acquired proprietary AI-powered compound modeling and sonodynamic therapy (SDT) optimization platform, and a patented magnetic-field-guided 3D bioprinting technology for tumor and disease modeling.
• NeOnc is listed on The Nasdaq Global Market under the symbol NTHI, with a last reported sale price of $8.96 per share on December 9, 2025.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring net losses and insufficient capital.
• Recent capital raises include $11,644,005 from private placements in March 2025, and sales of common stock totaling approximately $3,199,000 through an Equity Purchase Agreement with Mast Hill Fund, LP in July and September 2025, and an additional $750,000 in November 2025.
• A new private placement of 111,732 shares for $1.0 million was entered into on December 1, 2025, with Saad Naja at $8.95 per share.

Sentiment

Score: 3

Explanation: The company shows promising clinical progress and strategic technology acquisitions, which are positive for long-term potential. However, the immediate financial situation is highly concerning, marked by substantial and increasing net losses, a rapidly growing accumulated deficit, and an explicit 'going concern' warning from auditors. Significant reliance on continuous capital raises and unresolved litigation settlements further contribute to a high-risk profile, overshadowing the scientific advancements.

Positives

• NEO100 has completed Phase I clinical trials and is currently in Phase IIa trials for recurrent malignant glioma and malignant skull-based meningioma, showing preliminary signs of activity and good tolerability.
• NEO100 received Fast Track status in 2016 and Orphan Drug Designation in 2011 from the FDA for treating malignant glioma, offering incentives and potential market exclusivity.
• NEO212 has completed preclinical testing and received Investigational New Drug (IND) approval from the FDA, allowing it to proceed to clinical testing in cancer patients.
• NEO212 was granted Orphan Drug Designation (ODD) for three indications: glioma (2014), brain metastases from breast cancer (2017), and nasopharyngeal carcinoma (2017).
• The company has expanded the patient population for the NEO100 Phase IIa trial to include Grade III IDH1,2 mutant astrocytomas, which is expected to significantly expedite the trial process.
• A data readout for NEO100 Phase II studies is now projected by the end of Q1 2026, advancing the original timeline from 2025.
• Acquired proprietary AI-powered compound modeling and sonodynamic therapy (SDT) optimization platform to accelerate drug discovery and improve translational predictability.
• Acquired exclusive rights to a patented magnetic-field-guided 3D bioprinting platform for generating tumor spheroids and organoids, enhancing disease modeling and reducing reliance on animal models.
• Preclinical studies for intranasal NEO100 mixed with levodopa showed reversal of Parkinson's disease symptoms in mice, with a Phase I clinical trial planned.
• Preclinical studies suggest intra-arterial delivery of NEO100 may temporarily open the blood-brain barrier, allowing other therapeutic agents (e.g., trastuzumab, immune checkpoint antibodies, CAR T cells) to enter the brain, showing promising results in mouse models.

Negatives

• The company has incurred significant operating losses, with a net loss of $46,622,106 for the nine months ended September 30, 2025, and $11,898,464 for the year ended December 31, 2024.
• An accumulated deficit of $97,230,551 at September 30, 2025, and $50,608,445 at December 31, 2024, raises substantial doubt about the company's ability to continue as a going concern.
• Minimal revenue generation, with only $39,990 from humanitarian usage for the nine months ended September 30, 2025, and no significant product sales anticipated for the foreseeable future.
• Reliance on third-party contract manufacturers for all raw materials, active pharmaceutical ingredients, and finished products, which are subject to cGMP regulations and potential supply chain risks.
• Material weaknesses in internal control over financial reporting were identified as of September 30, 2025, related to segregation of duties, risk assessment, information and communication, monitoring processes, financial controls, related party transactions, and IT user access.
• The company is in default on a $600,000 litigation settlement payment to a vendor, which was due by March 31, 2024, and is now payable on demand with accrued interest.
• Orient EuroPharma Co., Ltd. (OEP) claims the company is currently obligated to pay a $4.0 million settlement amount, which the company disputes, posing a risk of additional legal proceedings and operational disruptions.
• Significant increase in general and administrative expenses, primarily due to a marketing campaign, increased employee headcount, and associated compensation and benefits, rent, and travel expenses.
• High share-based compensation expense of $25,964,096 for the nine months ended September 30, 2025, due to RSU grants and the listing date contingency removal.
• The company will need substantial additional funding to support continuing operations and growth strategy, with no assurance of obtaining it on acceptable terms or at all.

Risks

• Inability to raise additional funds or enter into collaboration agreements when needed, which could materially adversely affect business, results of operations, and financial condition.
• Uncertainty of successful completion of preclinical studies and clinical trials for current and future product candidates, including establishing appropriate safety profiles and demonstrating efficacy.
• Failure to obtain regulatory approvals from agencies like the FDA for product candidates, which is required before commercialization.
• Dependence on third-party manufacturers for drug product and supply, with risks related to compliance with cGMP regulations and potential supply disruptions.
• Inability to obtain and maintain patent and other intellectual property protection, or challenges to the validity and enforceability of existing patents, which could harm competitive advantage.
• Intense competition in the global central nervous system (CNS) treatment and brain tumor drug markets from large pharmaceutical companies, generics, and emerging therapies.
• Risks associated with being an emerging growth company and smaller reporting company, including reduced disclosure requirements that may make common stock less attractive to investors.
• Potential for significant penalties, litigation, and reputational harm from failure to comply with federal and state healthcare laws and regulations, including anti-kickback, false claims, and data privacy laws.
• Uncertainty regarding coverage and adequate reimbursement from third-party payors for any approved products, which could limit net revenue.
• Impact of health reform measures, including price controls and cost-containment programs, on product pricing and reimbursement.
• Risks related to data privacy and security, including potential breaches and non-compliance with evolving regulations like GDPR and CCPA, leading to investigations, fines, or operational disruptions.
• The company is currently in default on a $600,000 litigation settlement payment, and faces potential additional proceedings from Orient EuroPharma Co., Ltd. regarding a $4.0 million settlement, which could result in further costs and operational disruptions.
• The ability to utilize net operating loss carryforwards may be limited due to possible changes in ownership as defined under Internal Revenue Code section 382.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approval, expands its intellectual property portfolio, and operates as a public company. Substantial additional funding will be required, likely through equity offerings, debt financings, or collaboration agreements, with no guarantee of availability on acceptable terms. The company does not anticipate generating significant revenues for the foreseeable future.

Management Comments

• "We believe this targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite our trial process and we project that the readout for our Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025." (Note: This statement is from the Prospectus Summary, but the Business section later updates the projection to Q1 2026, indicating a delay from the earlier 'end of 2024' projection).
• "We believe this targeted enrolment pool may significantly expedite our trial process. With this refined focus, we are revising our protocol inclusion criteria to include Residual Measurable Disease (RMD) grade III IDH1 mutant patients. We believe this amendment to our enrolment criteria may markedly accelerate patient accrual, enhance the efficiency of our trials and may lead to quicker results. As a result of these changes, we project that the readout for our Phase II studies with respect to NEO100-01 could now be feasibly delivered by the end of first quarter of 2026."
• "We believe these three delivery areas (details below) may be key to a potential shift in physicians ability to treat brain diseases. They represent potential pathways for possible reliable delivery of pharma-therapeutics to the brain, potentially mitigating problems and side effects from current methodologies, and potentially providing an alternative treatment protocols to existing pharma manufacturers for their drugs."
• "Our goal is to change the cancer therapeutic landscape by developing novel therapeutic approaches leveraging dual approaches of novel drug delivery methods in combination with novel drug candidates that potentially lead to better therapeutic results with low side effects."
• "Notwithstanding the assessment that our internal controls over financial reporting are not effective and that material weaknesses exist, we believe that we have employed supplementary procedures to ensure that the financial statements contained in this filing fairly present our financial position, results of operations, and cash flows for the reporting periods covered herein in all material respects."

Industry Context

The global central nervous system (CNS) treatment market is projected to grow at an 8.6% CAGR to reach $267.6 billion by 2034, while the global brain tumor drug market is expected to grow at a 9.8% CAGR to $4.6 billion by 2032. Radiation therapy still dominates brain cancer treatment (38%), with drug treatment lagging due to delivery inefficiencies. The glioblastoma multiforme (GBM) drug market is also growing, driven by an aging population and rising incidence. NeOnc aims to disrupt this market with novel drug delivery mechanisms. Competition is intense, with established players like Pfizer, Roche, Novartis, Bristol Myers Squibb, Merck & Co., Novocure, AstraZeneca, Eli Lilly, and Celldex Therapeutics, as well as generics, biosimilars, and emerging biologics and gene therapies. The company's focus on targeted therapies and overcoming the blood-brain barrier positions it in a high-need, high-growth segment.

Comparison to Industry Standards

• NEO100's intranasal delivery aims to bypass the blood-brain barrier (BBB), a significant challenge for conventional systemic drug delivery to the brain, which is a common limitation for many existing CNS and brain cancer drugs.
• The Phase I trial results for intranasal NEO100 in recurrent glioblastoma patients showed several long-term survivors (37% at two years, 25% at three years), which is noteworthy compared to the average life expectancy of about six months for recurrent glioblastoma patients with traditional treatments.
• NEO100 appeared well-tolerated in Phase I, with only minor side effects like runny nose or nasal discomfort, contrasting with the well-known harsh toxicities (nausea, fatigue, anemia, hair loss) of many conventional chemotherapeutic agents like temozolomide (TMZ).
• NEO212, a conjugated molecule of temozolomide and perillyl alcohol, is designed to enhance BBB penetration compared to TMZ alone, which enters the brain sub-optimally and has modest therapeutic impact.
• Preclinical studies suggest NEO212 may overcome TMZ resistance in MGMT-positive tumors, a common challenge in glioblastoma treatment.
• The company's AI-powered compound modeling and 3D bioprinting platforms offer advanced drug discovery and disease modeling capabilities, aligning with industry trends towards precision oncology and reducing reliance on animal models, potentially accelerating development compared to traditional methods.
• The planned clinical trial for intranasal NEO100 with levodopa for Parkinson's disease aims to offer better brain-directed delivery and potentially fewer systemic side effects compared to oral L-Dopa pills, which have common side effects like hypotension, nausea, and dyskinesia.

Management Changes

Corporate Governance

Legal Proceedings

• The company is in default on a $600,000 litigation settlement payment to a vendor (Fox Infused, LLC) for breach of contract, which was due by March 31, 2024, and is now payable on demand with accrued interest from May 15, 2024.
• Orient EuroPharma Co., Ltd. (OEP) initiated arbitration claiming improper termination of a collaboration agreement and believes the company is currently obligated to pay a $4.0 million settlement amount, which the company disputes, posing a risk of additional legal proceedings.

Related Party Transactions

• **AFH Holdings and Advisory, LLC (AFH)**: Amir Heshmatpour (CEO, President, Executive Chairman) is the sole member and managing director. AFH was retained for advisory services related to public listing and financing. AFH earned a $500,000 fee in 2023 and $500,000 for an amendment in 2024. A fee of $11,328,565 was incurred on March 26, 2025, for the Nasdaq listing, with $2,500,000 paid upfront and the remaining $8,828,565 payable in 12 equal monthly installments. AFH also acts as an exclusive advisor for financing and M&A for two years post-public offering.
• **University of Southern California (USC)**: The company has an exclusive license agreement with USC for patented technology. USC was granted 117,236 shares of common stock in 2009 and 560,000 additional shares in October 2023. The company pays annual patent maintenance fees ($20,000) and 2-4% earned royalties on net sales (no royalties paid to date). The company also utilizes laboratory and patent maintenance services from USC, incurring $461,000 and $326,000 in R&D costs in 2024 and 2023, respectively. As of September 30, 2025, $499,607 was owed to USC. A $230,000 payment to cure deficiencies in the license agreement was recorded in 2023, with the payment date extended to September 1, 2025, or within five days of a public offering.
• **Accrued Compensation**: The company incurred $785,996 and $798,743 in compensation for the management team (all shareholders) in 2024 and 2023, respectively. As of September 30, 2025, $255,099 was accrued. In June 2024, $412,500 of accrued compensation was converted into 34,375 shares of common stock.
• **HCWG LLC**: An entity owned by Amir Heshmatpour (25.1%), Dr. Thomas C. Chen (25.5%), Keithly Garnett (4.3%), and others. In April 2023, the company entered into a non-interest bearing, non-convertible promissory note (Bridge Loan) with HCWG LLC, with borrowings up to $10,000,000. In June 2024, the outstanding principal and interest of $11,748,464 was converted into 979,039 shares of common stock. On October 11, 2024, the company entered into a new Line of Credit Agreement with HCWG for up to $10.0 million, bearing 10.0% interest, and issued a five-year warrant to purchase 312,500 shares. In March 2025, 162,500 shares were issued to HCWG upon cashless exercise of a warrant.
• **Executive Chairman (Amir Heshmatpour)**: Advanced approximately $300,000 to the company in February 2025, with a 50% original issue discount. The advance and 1x interest ($600,000 total) were repaid in March 2025.
• **Orient EuroPharma Co., Ltd. (OEP)**: Partially owned by Alan Chiang, a former director. A collaboration agreement from November 2013 was terminated via a settlement agreement in February 2024, requiring a $4,000,000 payment from the company.
• **Neucen Biomedical Co., Ltd. (NB)**: Owned in part by the spouse of Dr. Alan Chiang and Thomas Chen. A license agreement from December 2015 for NEO212 was mutually terminated in June 2023.

Stakeholder Impact

• **Shareholders**: Significant dilution from ongoing equity raises and share-based compensation. The substantial net losses and accumulated deficit, along with the 'going concern' warning, pose a high risk to investment value. The classified board structure and anti-takeover provisions may limit shareholder influence. However, clinical progress and new technology acquisitions offer potential long-term value if successful.
• **Employees**: Increased headcount and compensation expenses reflect growth in operations. Share-based compensation is a significant component of executive and director remuneration, aligning incentives with company performance, but also a large expense. The company's financial instability could impact job security if funding is not secured.
• **Customers/Patients**: The development of novel treatments for aggressive brain cancers and Parkinson's disease offers hope for patients with limited effective options. Successful clinical trials and regulatory approvals could provide significant therapeutic benefits and improve quality of life. Delays in trial readouts impact patient access to potential treatments.
• **Suppliers/Creditors**: The company's liquidity issues and default on a litigation settlement payment create risk for creditors. The reliance on third-party manufacturers means suppliers are critical to product development, but their payment could be affected by financial instability.
• **Regulatory Bodies**: The company is subject to rigorous FDA and other regulatory oversight for drug development, manufacturing, and marketing. Compliance failures could lead to significant penalties and delays in product approval.

Next Steps

• Continue Phase IIa clinical trials for intranasal NEO100 in recurrent malignant glioma and malignant skull-based meningioma patients.
• Initiate and complete Phase I/II trials for oral NEO212 in primary and secondary brain tumors.
• Plan and initiate a Phase I clinical trial for intranasal NEO100 mixed with levodopa for Parkinson's disease.
• Conduct further preclinical studies for other drug delivery pathways (combination therapy with NEO100, conjugated delivery, permeable delivery) to generate IND-enabling data.
• Remediate identified material weaknesses in internal control over financial reporting, including hiring additional financial personnel/consultants and migrating to Oracle NetSuite.
• Address and resolve outstanding litigation settlement payments, including the $600,000 to a vendor and the $4.0 million claim from OEP.
• Secure additional funding through equity offerings, debt financings, or collaboration agreements to support ongoing operations and growth strategy.
• Continue to develop and expand the intellectual property portfolio for product candidates.

Key Dates

Recommendation

Despite promising clinical trial progress for NEO100 and NEO212, and strategic acquisitions of AI and 3D bioprinting platforms, the company's financial health is in a critical state. The reported net loss of $46.6 million for the first nine months of 2025 and an accumulated deficit of $97.2 million are unsustainable. The explicit 'going concern' warning from auditors indicates a high probability of financial distress or failure without substantial, continuous, and successful capital raises. The company is already in default on a $600,000 litigation settlement and faces a potential $4.0 million claim, adding to its liabilities. While the scientific pipeline has potential, the severe and rapidly deteriorating financial position, coupled with the inherent risks of clinical-stage biopharmaceutical development and significant related-party transactions, presents an extremely high-risk investment. The continuous need for dilutive capital raises and the uncertainty of future funding on favorable terms make the stock highly speculative with significant downside risk.

Keywords

Biopharmaceutical, Brain Cancer, Glioblastoma, Meningioma, NEO100, NEO212, Intranasal Delivery, Drug Delivery, Clinical Trials, Orphan Drug, Fast Track, FDA Approval, AI Drug Discovery, 3D Bioprinting, Neuro-oncology, Parkinson's Disease, Blood-Brain Barrier, SEC Filing, S-1 Registration